This is a preview of subscription content, log in via an institution to check access.
Reference
Coman RM, et al. Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide-case report and literature review of the side effects of 5-aminosalicylates. Expert Review of Clinical Immunology 10: 667-675, No. 5, May 2014. Available from: URL: http://doi.org/10.1586/1744666X.2014.902313 - USA
Additional information
≫ Editorial comment: Details of this case report have previously been published [see Reactions 1480 p9; 803096306]. In the current article, the authors state that the man had started receiving balsalazide 1.5g (2 capsules) 3 times daily after being diagnosed with ulcerative colitis. His balsalazide dosage was increased to 2.25g (3 capsules) 3 times daily following ulcerative colitis flare. He presented 8–10 weeks later, with a 5-day history of fever, dyspnoea, fatigue and pleuritic chest pain; the first sign of balsalazide hypersensitivity and febrile pleuropericarditis. A positive rechallenge was consistent with this diagnosis.
Rights and permissions
About this article
Cite this article
Balsalazide. Reactions Weekly 1502, 10 (2014). https://doi.org/10.1007/s40278-014-0906-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-014-0906-6